SLS: Follow-up Interviews on Patient-Centred Outcomes (Asthma)

  • Research type

    Research Study

  • Full title

    Salford Lung Studies: Follow-up Interviews on Patient-Centred Outcomes Asthma Research Protocol

  • IRAS ID

    191609

  • Contact name

    Lydia Demetriou

  • Contact email

    lydia.x.demetriou@gsk.com

  • Sponsor organisation

    GlaxoSmithKline

  • Duration of Study in the UK

    1 years, 0 months, 0 days

  • Research summary

    This study involves conducting follow up interviews with people who have taken part in the Salford Lung Study (SLS, Asthma), which is a 12-month study of treatments in asthma. The SLS Asthma is being conducted in Salford as a collaboration between North West eHealth (NWeH), part of Salford Royal NHS Foundation Trust, the University of Manchester, GPs and community pharmacists in Salford, Trafford, South Manchester and Stockport and is sponsored by GlaxoSmithKline Research and Development Ltd (GSK).

    Interviews will be conducted with people shortly after they finish the SLS Asthma. The data collected in these interviews will build on information gathered in the SLS Asthma. It will provide a greater understanding of people’s experiences during the study, how they manage their condition day to day, their views and opinions on the treatment they received, and how these might have changed over the course of the study.

    Two types of follow up interviews will be conducted in this study: a standard interview (closed questions) and an extended interview (closed and open questions) either by telephone or face to face.

    Not all SLS participants will be interviewed for this study; up to 400 patients from SLS Asthma will participate in the short interview, with a subsample of 40 for the extended interview.

    During the interviews, each patient will be asked brief questions about their asthma, how it affects their daily life, their opinions about the treatments they received, and their experiences of these during the Salford Lung Study.

    There are no direct benefits for the patient from taking part in this study, but it is anticipated that the information they provide will aid understanding of people’s experiences of asthma and their treatment.

  • REC name

    North West - Preston Research Ethics Committee

  • REC reference

    15/NW/0853

  • Date of REC Opinion

    27 Oct 2015

  • REC opinion

    Favourable Opinion